Insider Trading Activity Acceleron Pharma Inc. (NASDAQ:XLRN) – SVP Sold 13,065 shares of Stock

ME Staff
-
0

Insider Trading Activity For Acceleron Pharma Inc. (NASDAQ:XLRN)

Ravindra Kumar , SVP of Acceleron Pharma Inc. (NASDAQ:XLRN) reportedly Sold 13,065 shares of the company’s stock at an average price of 35.41 for a total transaction amount of $462,631.65 SEC Form

Insider Trading History For Acceleron Pharma Inc. (NASDAQ:XLRN)

  • On 9/24/2013 Corp /De/ Celgene, Major Shareholder, bought 666,667 with an average share price of $15.00 per share and the total transaction amounting to $10,000,005.00.View SEC Filing
  • On 1/28/2014 Corp /De/ Celgene, Major Shareholder, bought 300,000 with an average share price of $50.00 per share and the total transaction amounting to $15,000,000.00.View SEC Filing
  • On 4/22/2014 Steven Ertel, SVP, sold 2,500 with an average share price of $35.87 per share and the total transaction amounting to $89,675.00.View SEC Filing
  • On 4/22/2014 Ravindra Kumar, VP, sold 2,000 with an average share price of $35.86 per share and the total transaction amounting to $71,720.00.View SEC Filing
  • On 4/24/2014 Edwin Kania, Jr., Director, sold 1,000,000 with an average share price of $32.05 per share and the total transaction amounting to $32,050,000.00.View SEC Filing
  • On 5/5/2014 Jean George, Director, sold 215,644 with an average share price of $42.86 per share and the total transaction amounting to $9,242,501.84.View SEC Filing
  • On 5/5/2014 Corp /De/ Celgene, major shareholder, bought 1,100,000 with an average share price of $42.86 per share and the total transaction amounting to $47,146,000.00.View SEC Filing

    • Analyst Ratings For Acceleron Pharma Inc. (NASDAQ:XLRN)
    These are 1 Sell Rating, 4 Hold Ratings, 10 Buy Ratings .
    The current consensus rating for Acceleron Pharma Inc. (NASDAQ:XLRN) is Buy (Score: 2.60) with a consensus target price of $42.31 , a potential (18.64% upside)

    Analyst Ratings History For Acceleron Pharma Inc. (NASDAQ:XLRN)

    • On 2/29/2016 Janney Montgomery Scott Upgraded rating Neutral to Buy with a price target of $45.00 to $39.00
    • On 6/13/2016 Barclays PLC Boost Price Target of rating Overweight with a price target of $40.00 to $42.00
    • On 8/19/2016 BTIG Research Initiated Coverage of rating Buy with a price target of $46.00
    • On 12/1/2016 Leerink Swann Set Price Target of rating Buy with a price target of $50.00
    • On 3/1/2017 Nomura Initiated Coverage of rating Buy
    • On 3/14/2017 J P Morgan Chase & Co Initiated Coverage of rating Neutral to Neutral with a price target of $33.00
    • On 5/1/2017 JMP Securities Reiterated Rating Outperform with a price target of $39.00

    Recent Trading Activity for Acceleron Pharma Inc. (NASDAQ:XLRN)
    Shares of Acceleron Pharma Inc. closed the previous trading session at 35.66 up +1.11 3.21% with 539,657 shares trading hands.